QGENQiagen N.V.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~8% a year FCF growth. Moderate growth expectations are priced in.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What QGEN's price assumes
Qiagen N.V. trades at 26.0× earnings against 36.7× for the median Diagnostics & Research name, cheaper than its own group.
Trailing P/E · Diagnostics & Research median 36.7 · cheaper than the typical name in its group
- Price / sales
- 1.20
Price / sales · as of 2025-FY
- Free cash flow yield
- 4.2%
Free cash flow yield · Diagnostics & Research median 2.9%
- Growth the price implies
- +8.1%
Growth the price implies · The price pays for +8.1% free cash flow growth a year for a decade; the business has delivered −8.2% a year over the last three.
Details›
- Price / bookas of 2025-FY
- 2.61
- EV / EBITas of 2025-FY
- 7.08
- EV / salesas of 2025-FY
- 1.30
- Healthcare median P/E503 names
- 27.9
- Diagnostics & Research median P/E33 names
- 36.7
- Free cash flow, trailing twelve months
- $453M
- Market capitalisation216.9 million shares, counted Dec 31, 2025
- $10.9B
- 3-year revenue growth
- −0.81%
- 3-year free cash flow growth
- −8.2%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Diagnostics & Research
Ranks #2 of 21 by RyuScore